Developer docs
API playgroundTry for free, no card

Search company profiles

Vita 34

Full company profile

uuid0007ftd

Namestring
Vita 34
Legal namestring
FamiCord AG
Websiteurl
vita34.de
Company typeenum
Private
Founded yearint
1997
Descriptiontext

Vita 34 is Germany's first private cord blood bank, founded in 1997 and headquartered in BioCity Leipzig, where it operates a GMP-certified laboratory and cryopreservation facility. The company provides private banking of umbilical cord blood (Nabelschnurblut), containing hematopoietic stem cells, and umbilical cord tissue (Nabelschnurgewebe), containing mesenchymal stem cells relevant to regenerative medicine. A distinguishing offering is the Familienoption (Family Option), under which stored cord blood is tested at no additional cost for suitability for family members beyond the donor child — a service Vita 34 states is unique in Germany. Samples are cryopreserved at approximately -180°C under pharmaceutical-grade quality controls, and the company has built research collaborations including with the University of Leipzig on mesenchymal stem cell applications.

Vita 34 generates revenue through a combination of one-time collection and processing fees and recurring long-term storage fees, with entry pricing around EUR 1,390 and multi-year contract structures. Its primary customer segment is expectant parents and families purchasing biological 'health insurance' against potential future disease, with documented storage outcomes across 80+ medical indications. Customer base exceeds 230,000 families across more than 20 countries, anchored in a domestic distribution network that partners with over 95% of German birth clinics for sample collection. Supporting channels include an online self-service configurator, toll-free inside sales, parent information evenings, webinars, baby fair participation, and a referral program.

Vita 34 was previously listed as Vita 34 AG and now operates as a subsidiary brand within FamiCord AG, which it identifies as Europe's largest private cord blood banking group. The corporate history includes multiple bolt-on acquisitions in the DACH region (Novel Pharma 2010, BioPlanta 2012, Stellacure 2014, Vivocell 2014, StemCare 2015, Seracell Pharma 2017), expanding both geographic reach and technical capabilities. Leadership is anchored by Prof. Emilian Snarski as Hematologist and Medical Director of FamiCord Group, supported by long-tenured scientific staff such as Dr. Marion Bartel leading specialist consulting. The company was recognized as 'Top StemCell Bank in Europe 2025'.

Short descriptiontext

Vita 34 is Germany's first private cord blood bank, providing cryopreservation of umbilical cord blood and tissue stem cells for over 230,000 families across 20+ countries. Operating as a brand within FamiCord AG, it sells one-time processing plus recurring storage services via a GMP-certified Leipzig facility and a network covering 95%+ of German birth clinics.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersLeipzig, Germany
HQ citystring
Leipzig
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cord blood banking, stem cell storage, tissue cryopreservation, family biobanking, newborn health services
Industry1 code
1Cell & Tissue Banking (biobanking, cord blood/tissue)
CodeHLAAAGAEPrimaryYes
NAICS code1 code
  • Blood and Organ Banks621991
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Private Cord Blood Banking
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Initial Collection and Processing Fee
TypeOne Time License
Description

One-time fee covering cord blood/tissue collection kit, medical questionnaire review, sample transport via specialized courier, laboratory processing and preparation for long-term storage.

vita34.de
2Long-term Storage Fee
TypeSubscription Recurring
Description

Annual or multi-year fees for ongoing cryopreservation of stem cell samples at -180°C in secure storage tanks.

vita34.de
3Stem Cell Preparation Release
TypeProfessional Services
Description

When stem cells are needed for medical treatment, Vita 34 handles the controlled release and transport of samples to treating medical facilities.

vita34.de
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others
Pricing details1 tier
1Starting package from 1,390 EUR
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Entry-level pricing for cord blood storage; additional fees may apply for cord tissue storage and extended payment plans.

vita34.de
GTM typeB2C
B2C
Offering typeServices
Services
Brand1 of 2 records shown
1Familienoption
Description

A unique service offering where stored cord blood is also tested for suitability for family members, not just the child.

vita34.de
+1 more record
Core offering1 text field

Vita 34 is Germany's first private stem cell bank, collecting, processing, and cryopreserving umbilical cord blood and cord tissue from newborns for long-term storage. The company offers the unique Familienoption (Family Option) service, which tests stored samples for compatibility with family members at no additional cost. Operations are performed in a GMP-certified laboratory in Leipzig, serving more than 230,000 customers across over 20 countries.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 60,000 cord blood transplants performed worldwide for 80+ diseases
+2 more records
Product overview1 text field

Vita 34 is Germany's #1 German stem cell bank and the largest in Europe, offering private cord blood and cord tissue banking services for personal and family health preservation. The company provides two core storage products: Nabelschnurblut (cord blood banking) for hematopoietic stem cells used in treating blood cancers, immune disorders, and metabolic diseases; and Nabelschnurgewebe (cord tissue banking) for mesenchymal stem cells relevant to regenerative medicine. A differentiating add-on is the Familienoption (Family Option), which at no extra cost tests stored samples for suitability with family members. Stem cells are cryopreserved at approximately -180°C in GMP-certified facilities in Leipzig, Germany, with processing, storage, and release handled under strict quality standards. The company serves over 230,000 customers from more than 20 countries and works with over 95% of German birth clinics.

Product and service1 record
1Cord Blood Banking
CategoryStem Cell Banking
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with EBMT for stem cell transplantation research and clinical standards. Vita 34 collaborates on advancing stem cell banking practices and transplantation outcomes.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Membership and collaboration with WMDA to maintain international standards for stem cell donor registries and cord blood banking globally.

3EAF-CBB (European Association of Families - Cord Blood Banking)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with European cord blood banking association to promote quality standards and family awareness about stem cell preservation.

vita34.de
4University of Leipzig - Hematology and Internal Oncology Department
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration on the effectiveness of mesenchymal stem cells from cord tissue in blood stem cell transplants. Joint project to suppress life-threatening immune reactions (GvHD). Funded by Sächsische Aufbaubank with 1.2 million euros. The project was nominated for the Health Media Award 2013.

vita34.de
Strategic tierCoreTypeOthers
Description

Vita 34 is part of the FamiCord Group, Europe's largest private cord blood bank. Prof. Emilian Snarski serves as Hematologist and Medical Director of FamiCord Group.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

US-headquartered private cord blood and cord tissue bank with very similar product offering (collection kit processing + long-term cryopreservation) and direct-to-consumer subscription storage model; one of the closest global comparables to Vita 34.

TypeDirect peer
Description

US cord blood and cord tissue bank offering private family banking with recurring storage fees and obstetrician/hospital collection partnerships — a direct functional peer for Vita 34.

TypeDirect peer
Description

One of the largest US private cord blood banks, storing hematopoietic and mesenchymal stem cells for family use on a recurring-storage subscription model — directly comparable core offering.

TypeDirect peer
Description

UK-based private cord blood and cord tissue bank; offers whole-blood and cord tissue storage with multi-year storage contracts — a closely overlapping European peer.

TypeDirect peer
Description

UK private stem cell bank focused on umbilical cord blood and tissue storage for family use with long-term subscription storage — closely comparable offering and B2C motion.

TypeBroad incumbent
Description

European-headquartered family stem cell banking group operating across multiple countries; broad incumbent with overlapping private cord blood and tissue banking services.

TypeBroad incumbent
Description

Parent network of which Vita 34 is the German brand — Europe's largest private cord blood banking platform operating multiple national brands (Vivocell, Stellacure, etc.); directly comparable in scope and model.

TypeRegional player
Description

Scandinavian/Nordic private cord blood bank with overlapping core service (private collection + long-term storage); comparable regional peer acquired by Vita 34/FamiCord for consolidation context.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Vita 34

Private Cord Blood Bankingvita34.de

Vita 34 is Germany's first private cord blood bank, providing cryopreservation of umbilical cord blood and tissue stem cells for over 230,000 families across 20+ countries. Operating as a brand within FamiCord AG, it sells one-time processing plus recurring storage services via a GMP-certified Leipzig facility and a network covering 95%+ of German birth clinics.

What Vita 34 does

Vita 34 is Germany's first private cord blood bank, founded in 1997 and headquartered in BioCity Leipzig, where it operates a GMP-certified laboratory and cryopreservation facility. The company provides private banking of umbilical cord blood (Nabelschnurblut), containing hematopoietic stem cells, and umbilical cord tissue (Nabelschnurgewebe), containing mesenchymal stem cells relevant to regenerative medicine. A distinguishing offering is the Familienoption (Family Option), under which stored cord blood is tested at no additional cost for suitability for family members beyond the donor child — a service Vita 34 states is unique in Germany. Samples are cryopreserved at approximately -180°C under pharmaceutical-grade quality controls, and the company has built research collaborations including with the University of Leipzig on mesenchymal stem cell applications.

Vita 34 generates revenue through a combination of one-time collection and processing fees and recurring long-term storage fees, with entry pricing around EUR 1,390 and multi-year contract structures. Its primary customer segment is expectant parents and families purchasing biological 'health insurance' against potential future disease, with documented storage outcomes across 80+ medical indications. Customer base exceeds 230,000 families across more than 20 countries, anchored in a domestic distribution network that partners with over 95% of German birth clinics for sample collection. Supporting channels include an online self-service configurator, toll-free inside sales, parent information evenings, webinars, baby fair participation, and a referral program.

Vita 34 was previously listed as Vita 34 AG and now operates as a subsidiary brand within FamiCord AG, which it identifies as Europe's largest private cord blood banking group. The corporate history includes multiple bolt-on acquisitions in the DACH region (Novel Pharma 2010, BioPlanta 2012, Stellacure 2014, Vivocell 2014, StemCare 2015, Seracell Pharma 2017), expanding both geographic reach and technical capabilities. Leadership is anchored by Prof. Emilian Snarski as Hematologist and Medical Director of FamiCord Group, supported by long-tenured scientific staff such as Dr. Marion Bartel leading specialist consulting. The company was recognized as 'Top StemCell Bank in Europe 2025'.

Vita 34 firmographics

Firmographics
Name
Vita 34
Legal name
FamiCord AG
Website
https://vita34.de
Company type
Private
Founded year
1997
Operating status
Operating
Headcount range
51–100 employees
Short description
Vita 34 is Germany's first private cord blood bank, providing cryopreservation of umbilical cord blood and tissue stem cells for over 230,000 families across 20+ countries. Operating as a brand within FamiCord AG, it sells one-time processing plus recurring storage services via a GMP-certified Leipzig facility and a network covering 95%+ of German birth clinics.
Ownership category
akta.pro rank

Vita 34 industry classification

Industry
Product category
Private Cord Blood Banking
NAICS
Blood and Organ Banks (621991)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro primary industry
Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

Keywords

  • Cord blood banking
  • Stem cell storage
  • Tissue cryopreservation
  • Family biobanking
  • Newborn health services

Where Vita 34 is headquartered

Location

Headquarters

HQ city
Leipzig
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Vita 34 business model

Business model
GTM type
B2C
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Initial Collection and Processing Fee: One-time fee covering cord blood/tissue collection kit, medical questionnaire review, sample transport via specialized courier, laboratory processing and preparation for long-term storage.
  2. Long-term Storage Fee: Annual or multi-year fees for ongoing cryopreservation of stem cell samples at -180°C in secure storage tanks.
  3. Stem Cell Preparation Release: When stem cells are needed for medical treatment, Vita 34 handles the controlled release and transport of samples to treating medical facilities.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractStarting package from 1,390 EUR

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

Vita 34 product offering

Product offering

Core offering

Vita 34 is Germany's first private stem cell bank, collecting, processing, and cryopreserving umbilical cord blood and cord tissue from newborns for long-term storage. The company offers the unique Familienoption (Family Option) service, which tests stored samples for compatibility with family members at no additional cost. Operations are performed in a GMP-certified laboratory in Leipzig, serving more than 230,000 customers across over 20 countries.

Product overview

Vita 34 is Germany's #1 German stem cell bank and the largest in Europe, offering private cord blood and cord tissue banking services for personal and family health preservation. The company provides two core storage products: Nabelschnurblut (cord blood banking) for hematopoietic stem cells used in treating blood cancers, immune disorders, and metabolic diseases; and Nabelschnurgewebe (cord tissue banking) for mesenchymal stem cells relevant to regenerative medicine. A differentiating add-on is the Familienoption (Family Option), which at no extra cost tests stored samples for suitability with family members. Stem cells are cryopreserved at approximately -180°C in GMP-certified facilities in Leipzig, Germany, with processing, storage, and release handled under strict quality standards. The company serves over 230,000 customers from more than 20 countries and works with over 95% of German birth clinics.

Differentiator

Problem solved

Functional benefit

Brands

  • Familienoption: A unique service offering where stored cord blood is also tested for suitability for family members, not just the child.
  • BioCity Leipzig

Products and services

  • Cord Blood Banking

Quantifiable outcome

  • Over 60,000 cord blood transplants performed worldwide for 80+ diseases
  • +2 more outcomes

Companies that use Vita 34

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles1 record

Vita 34 technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Vita 34 partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core.

  • EBMT (European Society for Blood and Marrow Transplantation)coreStrategic or Co-development PartnerPartnership with EBMT for stem cell transplantation research and clinical standards. Vita 34 collaborates on advancing stem cell banking practices and transplantation outcomes.
  • WMDA (World Marrow Donor Association)coreStrategic or Co-development PartnerMembership and collaboration with WMDA to maintain international standards for stem cell donor registries and cord blood banking globally.
  • EAF-CBB (European Association of Families - Cord Blood Banking)coreStrategic or Co-development PartnerPartnership with European cord blood banking association to promote quality standards and family awareness about stem cell preservation.
  • University of Leipzig - Hematology and Internal Oncology DepartmentcoreStrategic or Co-development PartnerResearch collaboration on the effectiveness of mesenchymal stem cells from cord tissue in blood stem cell transplants. Joint project to suppress life-threatening immune reactions (GvHD). Funded by Sächsische Aufbaubank with 1.2 million euros. The project was nominated for the Health Media Award 2013.
  • FamiCord AG (Parent Company)coreOthersVita 34 is part of the FamiCord Group, Europe's largest private cord blood bank. Prof. Emilian Snarski serves as Hematologist and Medical Director of FamiCord Group.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Vita 34 competitors and assessment

Company assessment

Direct peers

  • Cryo-Cell International: US-headquartered private cord blood and cord tissue bank with very similar product offering (collection kit processing + long-term cryopreservation) and direct-to-consumer subscription storage model; one of the closest global comparables to Vita 34.
  • ViaCord: US cord blood and cord tissue bank offering private family banking with recurring storage fees and obstetrician/hospital collection partnerships — a direct functional peer for Vita 34.
  • Cord Blood Registry (CBR): One of the largest US private cord blood banks, storing hematopoietic and mesenchymal stem cells for family use on a recurring-storage subscription model — directly comparable core offering.
  • Cells4Life: UK-based private cord blood and cord tissue bank; offers whole-blood and cord tissue storage with multi-year storage contracts — a closely overlapping European peer.
  • Smart Cells International: UK private stem cell bank focused on umbilical cord blood and tissue storage for family use with long-term subscription storage — closely comparable offering and B2C motion.

Broad incumbents

  • Cryo-Save (Esperite Group): European-headquartered family stem cell banking group operating across multiple countries; broad incumbent with overlapping private cord blood and tissue banking services.
  • FamiCord Group: Parent network of which Vita 34 is the German brand — Europe's largest private cord blood banking platform operating multiple national brands (Vivocell, Stellacure, etc.); directly comparable in scope and model.

Regional players

  • StemCare: Scandinavian/Nordic private cord blood bank with overlapping core service (private collection + long-term storage); comparable regional peer acquired by Vita 34/FamiCord for consolidation context.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

Vita 34 social profiles

Digital presence

Vita 34 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Vita 34 leadership team

Management profile

Number of profiles

Profiles5 records

Vita 34 subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Vita 34 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Vita 34 M&A and investment

M&A and investment

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vita 34

What does Vita 34 do?

Vita 34 is Germany's first private stem cell bank, collecting, processing, and cryopreserving umbilical cord blood and cord tissue from newborns for long-term storage. The company offers the unique Familienoption (Family Option) service, which tests stored samples for compatibility with family members at no additional cost. Operations are performed in a GMP-certified laboratory in Leipzig, serving more than 230,000 customers across over 20 countries.

Is Vita 34 a public or private company?

Vita 34 is a private company. It is classified as corporate owned and is currently operating.

When was Vita 34 founded?

Vita 34 was founded in 1997. It employs 51 to 100 people.

Where is Vita 34 based?

Vita 34 is headquartered in Leipzig, Germany, in the Europe region.

How does Vita 34 make money?

Three revenue lines are on record. Initial Collection and Processing Fee is the primary driver. The others are long-term Storage Fee and stem Cell Preparation Release.

Who are Vita 34's main competitors?

Direct peers on record are Cryo-Cell International, ViaCord, Cord Blood Registry (CBR), Cells4Life and Smart Cells International. Broad incumbents are Cryo-Save (Esperite Group) and FamiCord Group. StemCare is listed as a regional player.

Does Vita 34 have an API?

No public API is recorded for Vita 34.

What industry is Vita 34 in?

Vita 34's product category is Private Cord Blood Banking. Its primary akta.pro industry code is HLAAAGAE, Cell & Tissue Banking (biobanking, cord blood/tissue). Its NAICS code is 621991 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireDGAP-DD: Vita 34 AG englishHolger Födisch, a member of Vita 34 AG's administrative or supervisory body, disposed of shares on XETRA on October 19, 2016. The transaction involved 23,100 shares at €5.25 each, totaling €121,575.GlobeNewswireDGAP-DD: Vita 34 AG englishVita 34 AG notified DGAP of a repurchase agreement transaction on 2016-08-23, executed on the Frankfurt Stock Exchange. The transaction involved 91,960 shares at 4.18 EUR each, with the issuer responsible for the content.GlobeNewswireDGAP-AFR: Vita 34 AG: Preliminary announcement of the publication of financial reports according to Articles 37v, 37w, 37y of the WpHG [the German Securities Act]Vita 34 AG announced the publication of its annual financial report and group annual financial report on March 30, 2016, in German and English. The announcement was transmitted by DGAP, a service of EQS Group AG.GlobeNewswireDGAP-Adhoc: Vita 34 AG increases Earnings per Share by 81 percent to EUR 0.67 and attains an EBITDA Margin of 27.5 percentVita 34 AG reported fiscal 2015 results with EPS of EUR 0.67, up 81.1% from EUR 0.37, and an EBITDA margin of 27.5%. Operating revenues rose 22.1% to EUR 18.5 million, and the company exceeded its EBITDA forecast. The board proposed a 6.7% dividend increase to EUR 0.16 per share.GlobeNewswireDGAP-DD: Vita 34 AG englishDr. Hans-Georg Giering, a member of an administrative or supervisory body, purchased 4,000 shares of Vita 34 AG on Xetra on November 13, 2015. The transaction totaled €19,771.90 at a price of €4.942975 per share.GlobeNewswireDGAP-DD: Vita 34 AG englishHolger Födisch, a member of an administrative or supervisory body, sold 184 shares of Vita 34 AG on Xetra on October 7, 2015. The transaction totaled 973.36 EUR at a price of 5.29 EUR per share.GlobeNewswireDGAP-DD: Vita 34 AG englishDr. Holger Födisch, a member of an administrative or supervisory body, sold 4,800 shares of Vita 34 AG on 05.10.2015. The transaction totaled 25,680 EUR at a price of 5.35 EUR per share, with the deal executed in Frankfurt.GlobeNewswireDGAP-DD: Vita 34 AG englishHolger Födisch, a member of an administrative or supervisory body, sold 2,500 shares of Vita 34 AG on Xetra on October 5, 2015. The transaction totaled €13,362.50 at a price of €5.345 per share.GlobeNewswireDGAP-DD: Vita 34 AG englishHolger Födisch, a member of an administrative or supervisory body, sold 1,157 shares of Vita 34 AG on XETRA on September 23, 2015. The transaction totaled €6,120.53 at a price of €5.29 per share.